-
Benchmark Reaffirms "Buy" Rating for Halozyme Therapeutics (NASDAQ:HALO)
ソース: Buzz FX / 21 2 2025 09:51:13 America/New_York
Benchmark Reaffirms "Buy" Rating for Halozyme Therapeutics (NASDAQ:HALO) Written by MarketBeat February 21, 2025 Share Link copied to clipboard. Halozyme Therapeutics ( NASDAQ:HALO - Get Free Report ) 's stock had its "buy" rating reaffirme
Read more...